Universal CAR-T Cell Therapy for MM

Recruiting now · Not applicable

Conditions studied: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory

In brief

This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.

Key facts

Study ID

NCT07248176

Run by

Bioray Laboratories

People needed

6

Starts

2025-04-10

Expected to finish

2028-04-18

Last updated by the study team

2025-12-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Expected survival of at least 3 months;
• Subjects should have measurable disease that meets the IMWG 2016 criteria;
• Previously received at least two lines of prior anti-myeloma therapy ；
• Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ；
• BCMA positive；
• ECOG score 0-1；
• No severe impairment or suppression of liver, kidney, coagulation, bone marrow, or lung function.

You may not qualify if…

• Pregnant or breastfeeding women;
• History of other malignant tumors;
• Active autoimmune diseases requiring immunotherapy;
• Previously received allogeneic stem cell transplantation;
• Previous use of CAR-T cells or other genetically modified T cell therapies;
• Previously received targeted BCMA therapy;
• Severe cardiovascular disease;
• Active infection;
• Positive virology test;
• Clinically significant central nervous system (CNS) diseases or pathological changes.

Where it is running

• Shanghi Tongji Hospital (Tongji Hospital of Tongji University) — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.